Therapeutic Solutions International Completes Purchase of FDA Phase III JadiCell Stem Cell Investigational New Drug Application from University of Miami

Transfer of Trial Sponsorship Final Major Milestone before Initiation of Lung Failure Pivotal Clinical Trial

Excerpt from the Press Release:

CEANSIDE, Calif.–(BUSINESS WIRE)–Therapeutic Solutions International announced today the execution of a purchase agreement covering sponsorship and leadership of the FDA cleared Phase III pivotal trial assessing JadiCell adult stem cells for treatment of COVID-19 associated lung failure.

“This pivotal trial has significant implications not only to COVID-19 patients with severe lung compromise but also the significant population of patients suffering from acute respiratory distress syndrome (ARDS),” said Dr. Thomas Ichim, Director of the Company. “If the trial is successful, we anticipate FDA registration of JadiCell as the first cell based therapeutic to address ARDS which represents a multibillion-dollar market.”

The Company previously licensed issued patent # 9,803,176 B2 covering the composition of matter of the JadiCells and has filed nine additional patents on novel uses and combinations as well as one manufacturing patent. The purchase of the Investigational New Drug application allows the Company to run the clinical trial as an “Industry Sponsored” investigation as compared to “Investigator Initiated,” thus allowing full control of trial conduct.

As part of the trial organization, the Principal Investigator has been changed to Dr. James Veltmeyer and Therapeutic Solutions International, Inc as the Sponsor.

Click the button below to read the entire Press Release:

Continue Reading The Press Release